CollPlant Biotechnologies Ltd.

NasdaqGM:CLGN Stock Report

Market Cap: US$50.0m

CollPlant Biotechnologies Dividends and Buybacks

Dividend criteria checks 0/6

CollPlant Biotechnologies does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.02%

Buyback Yield

Total Shareholder Yield-0.02%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14
Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29
Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09
The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CLGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLGN's dividend payments have been increasing.


Dividend Yield vs Market

CollPlant Biotechnologies Dividend Yield vs Market
How does CLGN dividend yield compare to the market?
SegmentDividend Yield
Company (CLGN)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.5%
Analyst forecast (CLGN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate CLGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CLGN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CLGN has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 09:22
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Linda PomeroyEdison Investment Research
Swayampakula RamakanthH.C. Wainwright & Co.